

Innovation all for the patients



Roche A member of the Roche group

Roche Announces Updates on Retinal Vein Occlusion (RVO) for Vabysmo

TOKYO, October 10, 2023 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced today that Roche issued a press release regarding long-term results of its two phase III clinical trials (BALATON study and COMINO study) for Vabysmo® (faricimab) for retinal vein occlusion (RVO).

Please refer to the link below for details of the press release:

Roche's Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies

<https://www.roche.com/media/releases/med-cor-2023-10-10>

###